Reviva Pharmaceuticals Holdings, Inc. Common Stock
0.37
USD
Gesponsert
+0.01
+1.37%
09. Jan., 12:45 UTC -5
Offen
RVPH Ergebnisberichte
Positives Überraschungsverhältnis
RVPH übertreffen die 13 der letzten 18Schätzungen.
72%
Nächster Bericht
Datum des nächsten Berichts
30. März 2026
Estimate forQ4 25(Revenue/ EPS)
--
/
-$0.08
Implizierte Änderung vonQ3 25(Revenue/ EPS)
--
/
+33.33%
Implizierte Änderung vonQ4 24(Revenue/ EPS)
--
/
-46.67%
Reviva Pharmaceuticals Holdings, Inc. Common Stock earnings per share and revenue
On 13. Nov. 2025, RVPH reported earnings of -0.06 USD per share (EPS) for Q3 25, beating the estimate of -0.09 USD, resulting in a 39.46% surprise. Revenue reached --, compared to an expected --, with a 0.00% difference. The market reacted with a -7.19% price change (close before vs. close after earnings).
Looking ahead to Q4 25, 10 analysts forecast an EPS of -0.08 USD, with revenue projected to reach -- USD, implying an increase of 33.33% EPS, and increase of 0.00% in Revenue from the last quarter.
Industry Peers’ Earnings
Industry Peers' Earnings displays EPS earnings data from companies in the same industry. Click on a card to view more details.
Citius Pharmaceuticals Inc. Common
Report Date
26. Dez. 2025 For Q4 25
Estimate
-$0.49
Aktuell
-
Überraschung
-
FAQ
What were Reviva Pharmaceuticals Holdings, Inc. Common Stock's earnings and revenue for the latest quarter Q3 2025?
For Q3 2025, Reviva Pharmaceuticals Holdings, Inc. Common Stock reported EPS of -$0.06, beating estimates by 39.46%, and revenue of $0.00, 0% as expectations.
How did the market react to Reviva Pharmaceuticals Holdings, Inc. Common Stock's Q3 2025 earnings?
The stock price moved down -7.19%, changed from $0.54 before the earnings release to $0.50 the day after.
When is Reviva Pharmaceuticals Holdings, Inc. Common Stock expected to report next?
The next earning report is scheduled for 30. März 2026.
What are the forecasts for Reviva Pharmaceuticals Holdings, Inc. Common Stock's next earnings report?
Based on 10
analysts, Reviva Pharmaceuticals Holdings, Inc. Common Stock is expected to report EPS of -$0.08 and revenue of -- for Q4 2025.